Transcripts Ribomic Inc.

Stocks

Market Closed - Japan Exchange 10:30:00 02/10/2026 +04			5-day change	1st Jan Change
76.00 ^JPY	-5.00%		0.00%	-2.56%

08-24	Ribomic Announces Completion of Clinical Trial Site Establishment for the Phase 3 Clinical Trial of Umedaptanib Pegol in Achondroplasia	CI
08-13	Ribomic Inc. Provides Non-Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2027	CI

11/11/22	Ribomic Inc. Provides Non-Consolidated Earnings Guidance for the Year Ending March 31, 2023	CI
09/08/22	Ribomic Inc. Provides Non-Consolidated Earnings Guidance for the Year Ending March 31, 2023	CI
13/05/22	Ribomic Inc. Provides Non-Consolidated Earnings Guidance for the Full Year Ending March 31, 2022	CI
09/11/21	Ribomic Inc. Provides Non-Consolidated Earnings Guidance for the Year Ending March 31, 2022	CI
06/08/21	Ribomic Inc. Provides Non-Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2022	CI
25/05/21	Ribomic Inc. Provides Non-Consolidated Earnings Guidance for the Year Ending March 31, 2022	CI
12/02/21	Ribomic Inc. Provides Non-Consolidated Earnings Guidance for the Year Ending March 31, 2021	CI
07/08/20	Ribomic Inc. Provides Non-Consolidated Earnings Guidance for the Full Year Ending March 31, 2021	CI
14/05/20	Ribomic Inc. Provides Non-Consolidated Earnings Guidance for the Full Year Ending March 31, 2021	CI
07/02/20	Ribomic Inc. Provides Non-Consolidated Earnings Guidance for the Year Ending March 31, 2020	CI
27/11/19	Ribomic Inc. Provides Non-Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2020	CI
23/08/19	Ribomic Inc. Provides Non-Consolidated Earnings Guidance for the Year Ending March 31, 2020	CI
21/08/17	Ribomic Inc. Announces Non-Consolidated Earnings Results for the First Quarter Ended June 30, 2017; Provides Non-Consolidated Earnings Guidance for the Year Ending March 31, 2018	CI